Heart Failure precision medicine
THE HUGE BURDEN OF HEART FAILURE DISEASE
After discharge from a Heart Failure hospitalization, patients are at an unacceptably high risk of recurrent hospitalizations or death.
One major origin of post discharge events is the residual patient congestion that is not optimally alleviated at discharge.1 (In fact, many patients leave hospital before their diuretic therapy is optimized)
Another important fact is that patients are discharged before lifesaving renin angiotensin antagonists and mineralocorticoid receptor antagonists could be optimized to reach the highest tolerable doses.2
A wide clinical unmet need
GUIDELINES RECOMMEND (grade 1, level of evidence A) OPTIMIZING PHARMACOTHERAPY TO IMPROVE OUTCOMES FOR PATIENTS WITH HEART FAILURE
Optimizing medications belonging to the RAAS inhibitor class (ACE-Is, ARBs and MRAs) have been proven to improve survival and reduce hospitalizations in patients with heart failure.2 In addition, optimizing diuretics reduces volume overload, eases the signs and symptoms of pulmonary congestion and keeps patients out of hospital.2
THEN WHY ARE THESE LIFE-SAVING MEDICATION OFTEN UNDER-UTILIZED AND UNDER-DOSED ?
The concerns for raising serum potassium levels, worsening renal function, or inadequate decongestion limit the way these medicines are utilized and dosed.3
Complicating the management of patients with heart failure is the fact that physicians do not have simple, patient-friendly tools to easily keep track of these issues with their patients at home.
We know that optimizing care through disease management programs improves outcomes in patients with heart failure. Up until recently, the focus has been on monitoring pulmonary congestion so that physicians can optimize diuretic doses and reduce admissions.4
But this is only part of the solution.
We also need to be monitoring serum potassium and renal function so that physicians can optimize not just the dose of a diuretic, but also optimize doses of ACE-I, ARB or MRA.
With such a complete view of the status of their HF patient overtime, physicians would feel safe and confident so as to optimize medication precisely to each patient status.
What if we could…
If there was a way to reliably, simply and cost-effectively monitor serum potassium, renal function and the degree of congestion in our heart failure patients at home, could we then optimize the use of these life-saving medicines?
With a more comprehensive approach like this, we may be able to reduce not just hospital readmissions, but we may also be able to improve the quality of life and survival of HF patients.
What we do
CARDIORENAL: GIVING THE PHYSICIAN THE SAFETY NET HE NEEDS TO OPTIMIZE PHARMACOTHERAPY
CardioRenal is developing a simple, non-invasive medical device that will measure serum potassium, renal function and estimated plasma volume (as a surrogate for congestion) at the patient’s home and will provide the information to the patient’s physician in real time….
This medical device is being developed and therefore does not bear the CE-Mark.
This medical device is currently not commerciallys available
Behind the scene
Regulatory affairs director
People we works with
We are recruting to expand the team competences – Send your application to firstname.lastname@example.org
We currently welcome applications for the following positions:
Lets talk and meet
Come visit us
11 RUE DE TÉHÉRAN
11 RUE DE TÉHÉRAN
8 AVENUE DANTE - 67200 STRASBOURG
17 AVENUE DES MARTYRS